{
    "symbol": "RNLX",
    "quarter": 4,
    "year": 2022,
    "date": "2022-10-31 11:55:06",
    "content": "  Examples of these statements include, without limitation, the potential benefits including economic savings of KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects for KidneyIntelX if approved, including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail cost of chronic and end stage kidney disease, optimize care delivery, and improve patient outcomes, trends in our market and potential benefits of government policy change, the impact of COVID-19 and other world events on our business, our expectations for hiring, product development, strategic partnerships and collaborations, reimbursement decisions, clinical studies and regulatory submissions, our business strategies and future growth including plans, expectations and opportunities for financing our operations, and revenue projections and guidance. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open."
}